Reuters logo
BRIEF-Heat Biologics Meets Efficacy Endpoint in Phase 1B Lung Cancer Trial
March 13, 2017 / 2:48 PM / 6 months ago

BRIEF-Heat Biologics Meets Efficacy Endpoint in Phase 1B Lung Cancer Trial

March 13 (Reuters) - Heat Biologics Inc

* Heat biologics meets efficacy endpoint in its phase 1b lung cancer trial to progress to phase 2

* Data monitoring committee (dmc) determined that phase 1b safety endpoint was met

* There do not appear to be additional toxicities seen in Hs-110/Nivolumab combination compared to existing data on nivolumab alone

* 5 out of 15 patients treated with Hs-110/Nivolumab combination had 20% or greater tumor reduction Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below